Jazz Pharmaceuticals (JAZZ) Cash & Debt
Jazz Pharmaceuticals (JAZZ) has $0 in cash and equivalents with $5.36B in total debt, resulting in a net cash position of -$5.36B.
Cash & Equivalents
$0
Total Debt
$5.36B
Net Cash
-$5.36B
Cash Runway
—
Quarterly Balance Sheet
| Period | Cash | Total Debt | Net Cash | Total Assets | Total Equity |
|---|---|---|---|---|---|
| FY2025 Q3 | $0 | $5.36B | -$5.36B | $11.36B | $3.96B |
| FY2025 Q2 | $0 | $5.36B | -$5.36B | $10.94B | $3.71B |
| FY2025 Q1 | $0 | $5.37B | -$5.37B | $11.53B | $4.17B |
| FY2024 Q4 | $0 | $6.11B | -$6.11B | $12.01B | $4.09B |
| FY2024 Q3 | $0 | $6.11B | -$6.11B | $12.26B | $4.17B |
| FY2024 Q2 | $0 | $5.71B | -$5.71B | $11.36B | $3.76B |
| FY2024 Q1 | $0 | $5.71B | -$5.71B | $11.33B | $3.70B |
| FY2023 Q4 | $0 | $5.71B | -$5.71B | $11.39B | $3.74B |
Frequently Asked Questions
How much cash does JAZZ have?+
Cash and equivalents for Jazz Pharmaceuticals includes cash in bank accounts, money market funds, and short-term investments that can be quickly converted to cash. This figure comes from the company's most recent quarterly balance sheet filing.
What is Jazz Pharmaceuticals's debt situation?+
Total debt includes all short-term and long-term borrowings reported on the balance sheet. Cannabis companies often carry higher debt loads because limited access to traditional banking forces them to use alternative financing at higher interest rates. Compare JAZZ's debt-to-equity ratio to industry peers for context.
How long can JAZZ operate at its current burn rate?+
Cash runway is estimated by dividing cash on hand by the average monthly cash burn (negative operating cash flow). For Jazz Pharmaceuticals, this metric indicates how many months the company can continue operating without raising additional capital. Companies with less than 12 months of runway may need to raise capital soon, which could dilute shareholders.